Patient capital operates under different time horizons than institutional fund capital. A pension fund evaluating a private equity commitment models its returns across a 10-12 year fund lifecycle with specific vintage-year benchmarking and distribution expectations. A venture capital fund models returns across 7-10 year portfolio construction with power-law expectations. A public equity manager models returns across quarterly and annual rolling periods against index benchmarks. A patient capital operator (a family office, operator-investor, or long-horizon holding company) doesn't model returns the same way. The relevant time horizon is multi-generational, and the relevant benchmark isn't a vintage-year IRR comparison but what the capital compounds into across 20-30 years of holding durable operating businesses.

That difference in time horizon changes what makes an attractive investment. An asset that generates 8% cash-on-cash yield and compounds cash flow across three decades is different than an asset that promises 25% IRR over 5 years and requires a liquidity event to realize returns. Different investors value those assets differently, and for ophthalmology specifically, the first type of asset is what the specialty actually produces at the practice level.

This is historical compound math. What $500,000 allocated into different asset categories has historically produced across 25-year holding periods, using published benchmark data from institutional sources. None of this represents Verdira's projected returns, offering terms, or investment recommendations; it's category-level compound analysis that patient capital allocators already run internally when evaluating long-horizon asset classes.

The Benchmark Comparisons

At 4% annual compounding, $500,000 across 25 years produces approximately $1.33 million, a 2.67x multiple of original capital. This is the historical real floor for cash-equivalent and investment-grade bond portfolios after inflation adjustment. Vanguard's VCMM forward 10-year assumptions project US investment-grade bond returns in the 4.3-5.3% range, with the 4% rate representing the post-inflation baseline.

At 6% across the same 25-year horizon, the same starting capital produces approximately $2.15 million, a 4.29x multiple. This approximates the JP Morgan 2026 Long-Term Capital Market Assumptions projection for a diversified 60% equities / 40% bonds portfolio at roughly 6.7% nominal. JPM's specific projection as of September 2025 was 6.7% for US Large Cap equities and 6.7% for ACWI global equities over a 10-15 year horizon.

At 8%, the compounded outcome is approximately $3.42 million, a 6.85x multiple. This corresponds to Ludovic Phalippou's Public Market Equivalent (PME) corrected return calculations for private equity across 2006-2016 vintages, which delivered roughly 8.6% net-of-fees, broadly matching S&P 500 performance after accounting for fees and illiquidity. Phalippou's correction is published at SSRN in December 2024.

At 10%, the compounded outcome is approximately $5.41 million, a 10.83x multiple. This is the approximate S&P 500 nominal total return over the long-term historical period (~10.3% per Damodaran dataset and Slickcharts). Forward projections are substantially lower: Vanguard's VCMM December 2025 US equities range is 2.8-4.8% over 10 years, and GMO's 7-year forecast has US Large Cap real returns in deeply negative territory.

At 12%, the compounded outcome is approximately $8.50 million, a 17.0x multiple. This corresponds to Cambridge Associates' historical horizon IRRs for US private equity across longer time windows (roughly 13-18% at 15-25 year horizons, though Phalippou argues these overstate effective wealth compounding by 200-400 basis points annually versus realized returns).

These compound numbers are illustrative and historical, not projections. Different asset classes carry different return profiles and different risks, and the point of running them side-by-side is to demonstrate how differently the same capital behaves across 25-year holding periods depending on the underlying asset characteristics.

What This Looks Like as a Table

Compound math is deterministic when rates hold. What isn't deterministic is which asset classes actually deliver their historical benchmark rates across the next 25 years.

The Forward Projection Problem

Institutional capital market assumptions have shifted substantially since 2022. Vanguard's VCMM model as of December 2025 projects US equities at 2.8-4.8% nominal over the next 10 years, materially below the historical 10% figure. GMO's 7-year forecast has US Large Cap real returns in deeply negative territory (some prints as low as -4.2% real). These forward projections reflect elevated equity valuations (current S&P 500 CAPE in the 30+ range versus long-term average near 16) and compressed future returns. JP Morgan's 2026 LTCMA is marginally more optimistic at 6.7% for US Large Cap over 10-15 years but still well below historical averages, and Cambridge Associates' PE benchmark data shows horizon IRRs compressing as valuations and entry multiples have risen and exit environments have weakened.

What this means for forward return projections across asset classes: historical compounding rates are probably too optimistic for the next 25 years across public equity and traditional PE. The 10% and 12% columns above reflect where those asset classes historically sat, not where they're likely to sit across the next horizon. Which changes the comparative math. If public equities return 4-6% across the next 25 years instead of 10%, and PE-net-of-fees returns 6-8% instead of the 12% horizon IRR implied by historical data, the comparative attractiveness of durable private operating businesses (which don't have the valuation compression issues that developed markets face) improves significantly.

What Ophthalmology Practice Ownership Has Historically Produced

Published data on long-term ophthalmology practice compound returns isn't organized in the same standardized format as institutional asset class benchmarks, but the underlying cash flow economics are well-documented in American Academy of Ophthalmology AAOE benchmarking data and industry sources. A stabilized ophthalmology practice operating at AAOE median overhead (58% of revenue) generates approximately 15-25% post-physician-compensation cash flow margin on its revenue base: for a $2 million revenue practice, that produces $300,000-$500,000 in annual post-physician-comp operating cash flow beyond owner professional compensation, and for a $5 million revenue practice, that cash flow scales to $750,000-$1.25 million.

Ambulatory surgery center ownership adds another revenue stream. The 2025 Medicare cataract ASC facility fee is approximately $1,371, roughly 2.4 times the physician professional fee for the procedure, and a practice that owns its ASC captures both the professional fee and the facility fee for every case performed at the owned surgical facility. Reinvestment of practice cash flow into additional locations, additional subspecialty capability, additional ASC capacity, and additional ancillary services (optical, diagnostic imaging, aesthetic services) compounds the revenue and cash flow base across time. A $2 million solo practice that reinvests cash flow across 20 years can realistically become a $8-15 million multi-location practice with significantly expanded ancillary revenue.

Across longer holding periods, well-run ophthalmology practices have historically compounded at rates that match or exceed the 8% illustrative rate shown in the table above, particularly when reinvestment is active and subspecialty mix expands across time. The underlying demographic tailwinds (cataract volume growing ~40% over past 15 years, AMD and diabetic retinopathy prevalence projected to grow significantly through 2050) support continued revenue expansion independent of any pricing improvement.

The Structural Case for Patient Capital in Ophthalmology

The comparative compound math produces a specific structural conclusion for patient capital allocators. Public equities face valuation compression and forward-return contraction relative to historical benchmarks; the historical S&P 500 rate is unlikely to repeat across the next 25 years at current CAPE levels and competitive global capital market dynamics. Private equity faces fee drag (typically 3-4 percentage points annually net of management fees and carried interest) and secondary market weakness that has reduced realized distributions (DPI) relative to paper valuations (IRR). Phalippou's PME correction suggests net-of-fees PE has historically matched public markets despite the fee premium and illiquidity, and forward projections are not obviously better. Traditional fixed income offers minimal real return after inflation: JP Morgan LTCMA US aggregate bond projection of 4.3-5.3% nominal translates to approximately 2-3% real after inflation expectations.

Durable private operating businesses, the category that patient capital operators have historically built wealth through, face different dynamics. A well-run ophthalmology practice in 2026 doesn't have a CAPE-compression problem because practice valuations aren't set by public market multiples, doesn't have PE fee drag because it's not inside a fund structure, and isn't exposed to public market correlation because its cash flow depends on local demographic demand, Medicare reimbursement, and procedural volume rather than tech equity cycles or interest rate expectations. The comparative attractiveness of durable operating business ownership improves as alternatives compress, and institutional LPs are increasingly interested in "permanent capital" structures, while family offices with multi-generational wealth time horizons have historically favored direct operating business ownership over fund commitments.

Back to the Original Allocation

For a patient capital allocator with $500,000 to deploy across a 25-year horizon, the comparative math is structural. The historical benchmarks for public equities and traditional PE are probably too optimistic for forward projection, and the returns from durable private operating businesses match or exceed those benchmarks in the historical data and face fewer forward headwinds. American ophthalmology at the practice level generates cash flow economics that compound well at the 8-12% illustrative range shown above, particularly when combined with active reinvestment, ASC ownership, and demographic tailwinds. The specific practice-level returns depend on the specific practice (subspecialty mix, geography, operator quality, and capital structure all matter), and the category-level economics have historically been strong while the forward demographic drivers remain favorable.

What this doesn't mean is that patient capital should blindly allocate into any ophthalmology opportunity. Specific practice characteristics matter enormously, and the difference between a well-run cataract practice in a demographic-growth metro and a declining retina practice in a shrinking regional market is enormous. Asset selection within the category matters as much as category-level allocation. What this does mean is that for capital allocators whose time horizons match the category's economic structure (patient capital, multi-decade hold intent, and comfort with private operating businesses rather than liquid public markets), American ophthalmology practice ownership in 2026 presents structural characteristics that compare favorably against the comparable asset classes that institutional capital typically deploys into.

The compound math at 8% gets you to $3.42 million across 25 years. At 10% it's $5.41 million. Which rate a specific ophthalmology practice delivers depends on the practice, the operator, the capital structure, and 25 years of execution. The category-level structural economics are there, and for patient capital that's looking for durable operating businesses to compound across multi-generational time horizons, American ophthalmology at the practice level is one of the clearer opportunities available in US healthcare in 2026.

This article is for general educational purposes and is not legal or financial advice.

Verdira is a healthcare acquisition platform focused on ophthalmology practices. Physician ownership. Transparent structure. No volume quotas. If you're a practice owner thinking about succession or a physician exploring ownership, we're open to thoughtful conversations.

Contact info@verdira.com | 307-381-3734 | verdira.com